EPS (Diluted) for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current diluted EPS (TTM) is $2.26. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEPS (Diluted)Switch metric
TTM (last 4 quarters)
$2.26
YoY change
-206.9%
5Y CAGR
N/A
Peak year (2025)
$2.33
Latest annual
$2.33
EPS (Diluted) history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
EPS (Diluted) history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | EPS (Diluted) | YoY |
|---|---|---|---|---|
| 2025 | $2.33 | -206.9% | ||
| 2024 | $-2.18 | -38.1% | ||
| 2023 | $-3.52 | -62.2% | ||
| 2022 | $-9.30 | +29.2% | ||
| 2021 | $-7.20 | -3.5% | ||
| 2020 | $-7.46 | -8.0% | ||
| 2019 | $-8.11 | +7.1% | ||
| 2018 | $-7.57 | +39.7% | ||
| 2017 | $-5.42 | +13.2% | ||
| 2016 | $-4.79 | +38.8% | ||
| 2015 | $-3.45 | -28.9% | ||
| 2014 | $-4.85 | +234.5% | ||
| 2013 | $-1.45 | -31.3% | ||
| 2012 | $-2.11 | +55.1% | ||
| 2011 | $-1.36 | +30.8% | ||
| 2010 | $-1.04 | -8.8% | ||
| 2009 | $-1.14 | +78.1% | ||
| 2008 | $-0.64 | -71.0% | ||
| 2007 | $-2.21 | +102.8% | ||
| 2006 | $-1.09 | -44.4% | ||
| 2005 | $-1.96 | -28.7% | ||
| 2004 | $-2.75 | -89.6% | ||
| 2003 | $-26.56 | +112.8% | ||
| 2002 | $-12.48 | — |
EPS (Diluted) values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Alnylam Pharmaceuticals (ALNY) diluted EPS totalled $2.33 – plunged 206.9% year-over-year.
Across the available history, diluted EPS reached its high of $2.33 in 2025 and its low of $-26.56 in 2003.
Alnylam Pharmaceuticals (ALNY) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $13.16.
Alnylam Pharmaceuticals EPS (Diluted) by Year
Alnylam Pharmaceuticals EPS (Diluted) 2025: $2.33
Alnylam Pharmaceuticals diluted EPS in 2025 was $2.33, plunged 206.9% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals EPS (Diluted) 2024: $-2.18
Alnylam Pharmaceuticals diluted EPS in 2024 was $-2.18, plunged 38.1% below 2023.
Alnylam Pharmaceuticals EPS (Diluted) 2023: $-3.52
Alnylam Pharmaceuticals diluted EPS in 2023 was $-3.52, plunged 62.2% below 2022.
Alnylam Pharmaceuticals EPS (Diluted) 2022: $-9.30
Alnylam Pharmaceuticals diluted EPS in 2022 was $-9.30, grew 29.2% from 2021.
Alnylam Pharmaceuticals EPS (Diluted) 2021: $-7.20
Alnylam Pharmaceuticals diluted EPS in 2021 was $-7.20.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — EPS (Diluted)
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest diluted EPS.
| Company | EPS (Diluted) | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $23.03 | Healthcare |
| Eli Lilly and Company (LLY) | $22.95 | Healthcare |
| Amgen Inc. (AMGN) | $14.23 | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $13.23 | Healthcare |
| AstraZeneca PLC (AZN) | $13.08 | Healthcare |
| Johnson & Johnson (JNJ) | $11.03 | Healthcare |
| Merck & Co., Inc. (MRK) | $7.28 | Healthcare |
| AbbVie Inc. (ABBV) | $2.37 | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's diluted EPS?
- Latest reported diluted EPS for Alnylam Pharmaceuticals (ALNY) is $2.26 (period ending December 31, 2025).
How has Alnylam Pharmaceuticals diluted EPS changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) diluted EPS changed -206.9% year-over-year on the latest annual filing.
When did Alnylam Pharmaceuticals diluted EPS hit its highest annual value?
- Alnylam Pharmaceuticals diluted EPS reached its highest annual value of $2.33 in 2025.
What was Alnylam Pharmaceuticals diluted EPS in 2024?
- Alnylam Pharmaceuticals (ALNY) diluted EPS in 2024 was $-2.18.
What was Alnylam Pharmaceuticals diluted EPS in 2025?
- Alnylam Pharmaceuticals (ALNY) diluted EPS in 2025 was $2.33.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.